Professor Howard C Thomas

Publications


Journals

  • Khan SA; Emadossadaty S; Ladep NG; Thomas HC; Elliott P; Taylor-Robinson SD; Toledano MB. (Apr 2012). Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J Hepatol. 56:848-854. DOI.
  • Cowan ML; Thomas HC; Foster GR. (Apr 2011). Therapy for chronic viral hepatitis: current indications, optimal therapies and delivery of care. Clin Med. 11:184-189.
  • Hatzakis A; Wait S; Bruix J; Buti M; Carballo M; Cavaleri M; Colombo M; Delarocque-Astagneau E; et alDusheiko G; Esmat G; Esteban R; Goldberg D; Gore C; Lok ASF; Manns M; Marcellin P; Papatheodoridis G; Peterle A; Prati D; Piorkowsky N; Rizzetto M; Roudot-Thoraval F; Soriano V; Thomas HC; Thursz M; Valla D; van Damme P; Veldhuijzen IK; Wedemeyer H; Wiessing L; Zanetti AR; Janssen HLA. (1 Sep 2011). The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. JOURNAL OF VIRAL HEPATITIS. 18:1-16. DOI.
  • Sauvage VR; Levene AP; Nguyen HT; Wood TC; Kudo H; Concas D; Thomas HC; Thursz MR; et alGoldin RD; Anstee QM; Elson DS. (Jul 2011). Multi-excitation fluorescence spectroscopy for analysis of non-alcoholic fatty liver disease. Lasers Surg Med. 43:392-400. DOI.
  • Chambers JC; Zhang W; Sehmi J; Li X; Wass MN; Van der Harst P; Holm H; Sanna S; et alKavousi M; Baumeister SE; Coin LJ; Deng G; Gieger C; Heard-Costa NL; Hottenga JJ; Kühnel B; Kumar V; Lagou V; Liang L; Luan J; Vidal PM; Mateo Leach I; O'Reilly PF; Peden JF; Rahmioglu N; Soininen P; Speliotes EK; Yuan X; Thorleifsson G; Alizadeh BZ; Atwood LD; Borecki IB; Brown MJ; Charoen P; Cucca F; Das D; de Geus EJ; Dixon AL; Döring A; Ehret G; Eyjolfsson GI; Farrall M; Forouhi NG; Friedrich N; Goessling W; Gudbjartsson DF; Harris TB; Hartikainen AL; Heath S; Hirschfield GM; Hofman A; Homuth G; Hyppönen E; Janssen HL; Johnson T; Kangas AJ; Kema IP; Kühn JP; Lai S; Lathrop M; Lerch MM; Li Y; Liang TJ; Lin JP; Loos RJ; Martin NG; Moffatt MF; Montgomery GW; Munroe PB; Musunuru K; Nakamura Y; O'Donnell CJ; Olafsson I; Penninx BW; Pouta A; Prins BP; Prokopenko I; Puls R; Ruokonen A; Savolainen MJ; Schlessinger D; Schouten JN; Seedorf U; Sen-Chowdhry S; Siminovitch KA; Smit JH; Spector TD; Tan W; Teslovich TM; Tukiainen T; Uitterlinden AG; Van der Klauw MM; Vasan RS; Wallace C; Wallaschofski H; Wichmann HE; Willemsen G; Würtz P; Xu C; Yerges-Armstrong LM; Alcohol Genome-wide Association (AlcGen) Consortium; Diabetes Genetics Replication and Meta-analyses (DIAGRAM+) Study; Genetic Investigation of Anthropometric Traits (GIANT) Consortium; Global Lipids Genetics Consortium; Genetics of Liver Disease (GOLD) Consortium; International Consortium for Blood Pressure (ICBP-GWAS); Meta-analyses of Glucose and Insulin-Related Traits Consortium (MAGIC); Abecasis GR; Ahmadi KR; Boomsma DI; Caulfield M; Cookson WO; van Duijn CM; Froguel P; Matsuda K; McCarthy MI; Meisinger C; Mooser V; Pietiläinen KH; Schumann G; Snieder H; Sternberg MJ; Stolk RP; Thomas HC; Thorsteinsdottir U; Uda M; Waeber G; Wareham NJ; Waterworth DM; Watkins H; Whitfield JB; Witteman JC; Wolffenbuttel BH; Fox CS; Ala-Korpela M; Stefansson K; Vollenweider P; Völzke H; Schadt EE; Scott J; Järvelin MR; Elliott P; Kooner JS. (Nov 2011). Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet. 43:1131-1138. DOI.
  • Lim AK; Patel N; Eckersley RJ; Fitzpatrick J; Crossey MM; Hamilton G; Goldin RD; Thomas HC; et alVennart W; Cosgrove DO; Taylor-Robinson SD. (Oct 2011). A comparison of 31P magnetic resonance spectroscopy and microbubble-enhanced ultrasound for characterizing hepatitis c-related liver disease. J Viral Hepat. 18:e530-e534. DOI.
  • Wadsworth CA; Dixon PH; Wong JH; Chapman MH; McKay SC; Sharif A; Spalding DR; Pereira SP; et alThomas HC; Taylor-Robinson SD; Whittaker J; Williamson C; Khan SA. (2011). Genetic factors in the pathogenesis of cholangiocarcinoma. Dig Dis. 29:93-97. DOI.
  • Hashim Abdalla MS; Taylor-Robinson SD; Sharif AW; Williams HR; Crossey MM; Badra GA; Thillainayagam AV; Bansi DS; et alThomas HC; Waked IA; Khan SA. (Jun 2011). Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma. HPB (Oxford). 13:385-390. DOI.
  • Hussain SS; Cheent KS; Crossey MM; Khan SA; Jackson JE; Taylor-Robinson SD; Thomas HC. Taha HE (ed). (Oct 2010). Recurrent haemorrhage from facial arteriovenous malformations in decompensated cirrhosis of the liver: Lessons to be learnt. Nile Medical Journal. 2010;1:59-61. Nile Liver Journal. 1, 1:59-61. Publisher weblink Author weblink.
  • Hussein SS; Cheent KS; Khan SA; Jackson JE; Crossey MM; Thomas HC; Taylor-Robinson SD. Al-Mahtab M (ed); Rahman S (ed). (Oct 2010). Management of recurrent bleeding from facial arteriovenous malformations in end-stage liver disease. International Journal of Hepatology. 1, 1:53-54. Publisher weblink Author weblink.
  • Patel KD; Abeysekera KW; Marlais M; McPhail MJ; Thomas HC; Fitzpatrick JA; Lim AK; Taylor-Robinson SD; et alThomas EL. (Feb 2011). Recent advances in imaging hepatic fibrosis and steatosis. Expert Rev Gastroenterol Hepatol. 5:91-104. DOI.
  • Shariff MI; Gomaa AI; Cox IJ; Patel M; Williams HR; Crossey MM; Thillainayagam AV; Thomas HC; et alWaked I; Khan SA; Taylor-Robinson SD. (1 Apr 2011). Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J Proteome Res. 10:1828-1836. DOI.
  • Patel M; Shariff MI; Ladep NG; Thillainayagam AV; Thomas HC; Khan SA; Taylor-Robinson SD. (Apr 2012). Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract. 18:335-342. DOI.
  • Kallis YN; Robson AJ; Fallowfield JA; Thomas HC; Alison MR; Wright NA; Goldin RD; Iredale JP; et alForbes SJ. (Apr 2011). Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response. Gut. 60:525-533. DOI.
  • Bridge SH; Sheridan DA; Felmlee DJ; Nielsen SU; Thomas HC; Taylor-Robinson SD; Neely RD; Toms GL; et alBassendine MF. (May 2011). Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection. Gut. 60:680-687. DOI.
  • Wylezinska M; Cobbold JF; Fitzpatrick J; McPhail MJ; Crossey MM; Thomas HC; Hajnal JV; Vennart W; et alCox IJ; Taylor-Robinson SD. (Apr 2011). A comparison of single-voxel clinical in vivo hepatic 31P MR spectra acquired at 1.5 and 3.0 Tesla in health and diseased states. NMR Biomed. 24:231-237. DOI.
  • Cobbold JFL; Anstee QM; Thomas HC. (30 Jul 2010). Rational Testing Investigating mildly abnormal serum aminotransferase values. BRITISH MEDICAL JOURNAL. 341. DOI.
  • Cobbold JF; Anstee QM; Thomas HC. (2010). Investigating mildly abnormal serum aminotransferase values. BMJ. 341:c4039.
  • Sharif AW; Williams HR; Lampejo T; Khan SA; Bansi DS; Westaby D; Thillainayagam AV; Thomas HC; et alCox IJ; Taylor-Robinson SD. (Aug 2010). Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy. HPB (Oxford). 12:396-402. DOI.
  • Anstee QM; Concas D; Kudo H; Levene A; Pollard J; Charlton P; Thomas HC; Thursz MR; et alGoldin RD. (Sep 2010). Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol. 53:542-550. DOI.
  • McPhail MJ; Bajaj JS; Thomas HC; Taylor-Robinson SD. (Jun 2010). Pathogenesis and diagnosis of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol. 4:365-378. DOI.
  • McPhail MJ; Senvar N; Thomas HC; Taylor-Robinson SD. (Nov 2010). Modern progress in hepatic encephalopathy. QJM. 103:899-900. DOI.
  • Patel JH; Cobbold JF; Thomas HC; Taylor-Robinson SD. (May 2010). Hepatitis C and hepatic steatosis. QJM. 103:293-303. DOI.
  • Taylor-Robinson SD; Cobbold JF; Thomas HC. (Feb 2010). Liver stiffness measurements in acute hepatitis B: implications for clinical practice. Eur J Gastroenterol Hepatol. 22:133-134. DOI.
  • Lim AK; Patel N; Eckersley RJ; Cobbold JF; Crossey MM; Cosgrove DO; Goldin RD; Thomas HC; et alTaylor-Robinson SD. (Nov 2010). Hepatic vein transit times of a microbubble agent in assessing response to antiviral treatment in patients with chronic hepatitis C. J Viral Hepat. 17:778-783. DOI.
  • Shariff MI; Ladep NG; Cox IJ; Williams HR; Okeke E; Malu A; Thillainayagam AV; Crossey MM; et alKhan SA; Thomas HC; Taylor-Robinson SD. (5 Feb 2010). Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J Proteome Res. 9:1096-1103. DOI.
  • Cobbold JF; Patel JH; Goldin RD; North BV; Crossey MM; Fitzpatrick J; Wylezinska M; Thomas HC; et alCox IJ; Taylor-Robinson SD. (Jan 2010). Hepatic lipid profiling in chronic hepatitis C: an in vitro and in vivo proton magnetic resonance spectroscopy study. J Hepatol. 52:16-24. DOI.
  • Cobbold JF; Crossey MM; Colman P; Goldin RD; Murphy PS; Patel N; Fitzpatrick J; Vennart W; et alThomas HC; Cox IJ; Taylor-Robinson SD. (Aug 2010). Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C. J Viral Hepat. 17:537-545. DOI.
  • Patel N; Forton DM; Hamilton G; Coutts GA; Thomas HC; Taylor-Robinson SD. (1 Apr 2001). Intracellular pH of the brain in chronic hepatic encephalopathy: An in vivo phosphorus-31 MR spectroscopy study. JOURNAL OF HEPATOLOGY. 34:52-52. Author weblink DOI.
  • Khan SA; Thomas HC; Davidson BR; Taylor-Robinson SD. (20 May 2006). Cholangiocarcinoma (vol 366, pg 1303, 2005). LANCET. 367:1656-1656. Author weblink.
  • Adenugba A; Khan SA; Taylor-Robinson SD; Cox IJ; Toledano MB; Thillainayagam AV; Bansi DS; Thomas HC; et alGibson RW; Beck AJ. (Aug 2009). Polychlorinated biphenyls in bile of patients with biliary tract cancer. Chemosphere. 76:841-846. DOI.
  • Kennedy PT; Lee HC; Jeyalingam L; Malik R; Karayiannis P; Muir D; Main J; Thursz M; et alGoldin R; Smith B; Brown A; Thomas HC. (2008). NICE guidelines and a treatment algorithm for the management of chronic hepatitis B: a review of 12 years experience in west London. Antivir Ther. 13:1067-1076.
  • Cobbold JF; Anstee QM; Goldin RD; Williams HR; Matthews HC; North BV; Absalom N; Thomas HC; et alThursz MR; Cox RD; Taylor-Robinson SD; Cox IJ. (Mar 2009). Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. Clin Sci (Lond). 116:403-413. DOI.
  • Grier S; Patel N; Kuo YT; Cosgrove DO; Goldin RC; Thomas HC; Taylor-Robinson SD; Lim AK. (Mar 2010). Perihepatic lymph nodes as markers of disease response in patients with hepatitis C-related liver disease: a prospective clinical evaluation. Eur J Gastroenterol Hepatol. 22:257-263. DOI.
  • Forton DM; Hamilton G; Allsop JM; Grover VP; Wesnes K; O'Sullivan C; Thomas HC; Taylor-Robinson SD. (Sep 2008). Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol. 49:316-322. DOI.
  • Godkin A; Ng WF; Gallagher K; Betts G; Thomas HC; Lechler RI. (May 2008). Expansion of hepatitis C-specific CD4+CD25+ regulatory T cells after viral clearance: a mechanism to limit collateral damage?. J Allergy Clin Immunol. 121:1277-1284.e3. DOI.
  • Jammeh S; Tavner F; Watson R; Thomas HC; Karayiannis P. (Apr 2008). Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. J Gen Virol. 89:901-909. DOI.
  • Jammeh S; Thomas HC; Karayiannis P. (1 Oct 2007). Replicative competence of the T131I, K141E, and G145R surface variants of hepatitis B virus. JOURNAL OF INFECTIOUS DISEASES. 196:1010-1013. Author weblink DOI.
  • Hennig BJ; Frodsham AJ; Hellier S; Knapp S; Yee LJ; Wright M; Zhang L; Thomas HC; et alThursz M; Hill AV. (1 Oct 2007). Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. LIVER INTERNATIONAL. 27:1134-1143. Author weblink DOI.
  • Thomas HC. (Oct 2007). Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). J Hepatol. 47:588-597. DOI.
  • Cobbold JF; Wylezinska M; Cunningham C; Crossey ME; Thomas HC; Cox IJ; Patel N; Taylor-Robinson SD. (Nov 2006). Non-invasive evaluation of hepatic fibrosis using magnetic resonance and ultrasound techniques. Gut. 55:1670.
  • Cox IJ; Sharif A; Cobbold JFL; Thomas HC; Taylor-Robinson SD. (14 Aug 2006). Current and future applications of in vitro magnetic resonance spectroscopy in hepatobiliary disease. WORLD J GASTROENTERO. 12:4773-4783.
  • Cox IJ; Sharif A; Cobbold JF; Thomas HC; Taylor-Robinson SD. (14 Aug 2006). Current and future applications of in vitro magnetic resonance spectroscopy in hepatobiliary disease. World J Gastroenterol. 12:4773-4783.
  • Wright M; Grieve R; Roberts J; Main J; Thomas HC; UK Mild Hepatitis C Trial Investigators. (Jul 2006). Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 10:1-iii.
  • Lim AK; Patel N; Eckersley RJ; Goldin RD; Thomas HC; Cosgrove DO; Taylor-Robinson SD; Blomley MJ. (Jul 2006). Hepatic vein transit time of SonoVue: a comparative study with Levovist. Radiology. 240:130-135. DOI.
  • Grier S; Lim AK; Patel N; Cobbold JF; Thomas HC; Cox IJ; Taylor-Robinson SD. (14 Jun 2006). Role of microbubble ultrasound contrast agents in the non-invasive assessment of chronic hepatitis C-related liver disease. World J Gastroenterol. 12:3461-3465.
  • Frodsham AJ; Zhang L; Dumpis U; Taib NA; Best S; Durham A; Hennig BJ; Hellier S; et alKnapp S; Wright M; Chiaramonte M; Bell JI; Graves M; Whittle HC; Thomas HC; Thursz MR; Hill AV. (13 Jun 2006). Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci U S A. 103:9148-9153. DOI.
  • Grover VP; Dresner MA; Forton DM; Counsell S; Larkman DJ; Patel N; Thomas HC; Taylor-Robinson SD. (21 May 2006). Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy. World J Gastroenterol. 12:2969-2978.
  • Khan SA; Taylor-Robinson SD; Carmichael PL; Habib N; Lemoine NR; Thomas HC. (May 2006). Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma. Int J Oncol. 28:1269-1277.
  • Forton DM; Taylor-Robinson SD; Thomas HC. (Apr 2006). Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol. 18:333-338.
  • Hamilton G; Allsop JM; Patel N; Forton DM; Thomas HC; O'Sullivan CP; Hajnal JV; Taylor-Robinson SD. (Apr 2006). Variations due to analysis technique in intracellular pH measurements in simulated and in vivo 31P MR spectra of the human brain. J Magn Reson Imaging. 23:459-464. DOI.
  • Vig P; Russo FP; Edwards RJ; Tadrous PJ; Wright NA; Thomas HC; Alison MR; Forbes SJ. (Feb 2006). The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice. Hepatology. 43:316-324. DOI.
  • Godkin A; Openshaw P; Thomas HC. (Nov 2005). Immune tolerance to hepatitis C virus acquired during engraftment of bone marrow transplant. J Viral Hepat. 12:604-608. DOI.
  • Khan SA; Thomas HC; Davidson BR; Taylor-Robinson SD. (8 Oct 2005). Cholangiocarcinoma. Lancet. 366:1303-1314. DOI.
  • Forton DA; Allsop JA; Cox IJ; Hamilton G; Wesnes K; Thomas HC; Taylor-Robinson SD. (1 Oct 2005). A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS. 19:S53-S63. Author weblink DOI.
  • Khan SA; Thomas HC; Toledano MB; Cox IJ; Taylor-Robinson SD. (Aug 2005). p53 Mutations in human cholangiocarcinoma: a review. Liver Int. 25:704-716. DOI.
  • Khan SA; Cox IJ; Thillainayagam AV; Bansi DS; Thomas HC; Taylor-Robinson SD. (Jul 2005). Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer. Eur J Gastroenterol Hepatol. 17:733-738.
  • Lim AK; Patel N; Eckersley RJ; Kuo YT; Goldin RD; Thomas HC; Cosgrove DO; Taylor-Robinson SD; et alBlomley MJ. (Jun 2005). Can Doppler sonography grade the severity of hepatitis C-related liver disease?. AJR Am J Roentgenol. 184:1848-1853.
  • Khan SA; Cox IJ; Hamilton G; Thomas HC; Taylor-Robinson SD. (Apr 2005). In vivo and in vitro nuclear magnetic resonance spectroscopy as a tool for investigating hepatobiliary disease: a review of H and P MRS applications. Liver Int. 25:273-281. DOI.
  • Hoare J; Waddington S; Thomas HC; Coutelle C; McGarvey MJ. (Mar 2005). Complement inhibition rescued mice allowing observation of transgene expression following intraportal delivery of baculovirus in mice. J Gene Med. 7:325-333. DOI.
  • Forton DM; Patel N; Oatridge A; Hamilton G; Hajnal JV; Thomas HC; Taylor-Robinson SD; Prince M; et alGoldblatt J; Bassendine M; Jones DEJ. (1 Mar 2005). Fatigue in primary biliary cirrhosis. GUT. 54:438-438. Author weblink.
  • Karayiannis P; Thomas HC. (Mar 2005). Is lamivudine a safe and effective therapy for patients with chronic hepatitis B and advanced liver disease?. Nat Clin Pract Gastroenterol Hepatol. 2:138-139. DOI.
  • Lim AK; Taylor-Robinson SD; Patel N; Eckersley RJ; Goldin RD; Hamilton G; Foster GR; Thomas HC; et alCosgrove DO; Blomley MJ. (Jan 2005). Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut. 54:128-133. DOI.
  • Wright M; Forton D; Main J; Goldin R; Torok E; Tedder R; Grant P; Thursz M; et alNaoumov N; Millson C; Mills PR; Bassendine M; Thomas HC; UK Mild HCV Trial investigators. (Jan 2005). Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat. 12:58-66. DOI.
  • Forton DM; Thomas HC; Taylor-Robinson SD. (Dec 2004). Central nervous system involvement in hepatitis C virus infection. Metab Brain Dis. 19:383-391.
  • Luik A; Knapp S; Thursz M; Thomas HC; Schlaaki JF. (1 Oct 2004). Autoregulatory role of interleukin-10 in hepatitis C patients treated with IFN-alpha. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 24:585-593. Author weblink DOI.
  • Yee LJ; Kelleher P; Goldin RD; Marshall S; Thomas HC; Alberti A; Chiaramonte M; Braconier JH; et alHall AJ; Thursz MR. (1 Sep 2004). Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. JOURNAL OF VIRAL HEPATITIS. 11:459-464. Author weblink DOI.
  • Forton DM; Karayiannis P; Mahmud N; Taylor-Robinson SD; Thomas HC. (May 2004). Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol. 78:5170-5183.
  • Yee LJ; Knapp S; Burgner D; Hennig BJ; Frodsham AJ; Wright M; Thomas HC; Hill AV; et alThursz MR. (May 2004). Inducible nitric oxide synthase gene (NOS2A) haplotypes and the outcome of hepatitis C virus infection. Genes Immun. 5:183-187. DOI.
  • Forton DM; Patel N; Prince M; Oatridge A; Hamilton G; Goldblatt J; Allsop JM; Hajnal JV; et alThomas HC; Bassendine M; Jones DE; Taylor-Robinson SD. (Apr 2004). Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels. Gut. 53:587-592.
  • Waters JA; Thomas HC. (2004). Determining the precursor frequency of HBV nucleocapsid antigen-specific T cells. Methods Mol Med. 96:85-88. DOI.
  • Karayiannis P; Main J; Thomas HC. (2004). Hepatitis vaccines. Br Med Bull. 70:29-49. DOI.
  • Hellier S; Frodsham AJ; Hennig BJW; Klenerman P; Knapp S; Ramaley P; Satsangi J; Wright M; et alZhang LN; Thomas HC; Thursz M; Hill AVS. (1 Dec 2003). Association of genetic variants of the chemokine receptor MRS and its ligands, RANTES and MCP-2, with outcome of HCV infection. HEPATOLOGY. 38:1468-1476. Author weblink DOI.
  • Thomas HC. (1 Nov 2003). Hepatology in the UK. HEPATOLOGY. 38:1087-1088. Author weblink.
  • Knapp S; Hennig BJ; Frodsham AJ; Zhang L; Hellier S; Wright M; Goldin R; Hill AV; et alThomas HC; Thursz MR. (Sep 2003). Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics. 55:362-369. DOI.
  • Knapp S; Yee LJ; Frodsham AJ; Hennig BJ; Hellier S; Zhang L; Wright M; Chiaramonte M; et alGraves M; Thomas HC; Hill AV; Thursz MR. (Sep 2003). Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 4:411-419. DOI.
  • Forton DM; Thomas HC; Taylor-Robinson SD. (1 Aug 2003). Quality of life and cognitive function in chronic hepatitis C - what to measure?. JOURNAL OF HEPATOLOGY. 39:272-274. Author weblink DOI.
  • Khan SA; Carmichael PL; Taylor-Robinson SD; Habib N; Thomas HC. (Apr 2003). DNA adducts, detected by 32P postlabelling, in human cholangiocarcinoma. Gut. 52:586-591.
  • Forton DM; Taylor-Robinson SD; Thomas HC. (Mar 2003). Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat. 10:81-86.
  • Gaud U; Langer B; Petropoulou T; Thomas HC; Karayiannis P. (Mar 2003). Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects. J Med Virol. 69:350-356. DOI.
  • Dick EA; Joarder R; de Jode M; Taylor-Robinson SD; Thomas HC; Foster GR; Gedroyc WM. (Feb 2003). MR-guided laser thermal ablation of primary and secondary liver tumours. Clin Radiol. 58:112-120.
  • Khan SA; Taylor-Robinson SD; Toledano MB; Beck A; Elliott P; Thomas HC. (Dec 2002). Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 37:806-813.
  • Khan SA; Davidson BR; Goldin R; Pereira SP; Rosenberg WMC; Taylor-Robinson SD; Thillainayagam AV; Thomas HC; et alThursz MR; Wasan H. (1 Nov 2002). Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. GUT. 51:1-9. Author weblink.
  • Khan SA; Davidson BR; Goldin R; Pereira SP; Rosenberg WM; Taylor-Robinson SD; Thillainayagam AV; Thomas HC; et alThursz MR; Wasan H; British Society of Gastroenterology. (Nov 2002). Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 51 Suppl 6:VI1-VI9.
  • Forton DM; Wright M; Knapp S; Thursz MR; Taylor-Robinson SD; Thomas HC. (Nov 2002). New insights into hepatitis C. Clin Med. 2:554-559.
  • Hennig BJ; Hellier S; Frodsham AJ; Zhang L; Klenerman P; Knapp S; Wright M; Thomas HC; et alThursz M; Hill AV. (Sep 2002). Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun. 3:359-367. DOI.
  • Godkin AJ; Thomas HC; Openshaw PJ. (15 Aug 2002). Evolution of epitope-specific memory CD4(+) T cells after clearance of hepatitis C virus. J Immunol. 169:2210-2214.
  • Forbes S; Vig P; Poulsom R; Thomas H; Alison M. (Jul 2002). Hepatic stem cells. J Pathol. 197:510-518. DOI.
  • Dick EA; Taylor-Robinson SD; Thomas HC; Gedroyc WM. (May 2002). Ablative therapy for liver tumours. Gut. 50:733-739.
  • Lim AKP; Patel N; Hamilton G; Blomley MJK; Cosgrove DO; Foster GR; Goldin RD; Thomas HC; et alTaylor-Robinson SD. (1 Apr 2002). A prospective assessment of hepatic vein transit times using microbubble-enhanced ultrasound in non-invasive grading of hepatitis C (HCV) related liver disease. GUT. 50:A53-A53. Author weblink.
  • Khan SA; Carmichael PL; Taylor-Robinson SD; Habib N; Thomas HC. (1 Apr 2002). Evidence of an environmental cause for the rise in cholangiocarcinoma. GUT. 50:A54-A54. Author weblink.
  • Forton DM; Prince M; Allsop J; Patel N; Goldblatt J; Thomas HC; Bassendine M; Jones DEJ; et alTaylor-Robinson SD. (1 Apr 2002). Reduced pallidal magnetisation transfer ratios are associated with fatigue in pre-cirrhotic patients with primary biliary cirrhosis. GUT. 50:A46-A46. Author weblink.
  • Forton DM; Taylor-Robinson SD; Thomas HC. (Mar 2002). Reduced quality of life in hepatitis C--is it all in the head?. J Hepatol. 36:435-438.
  • Forton DM; Thomas HC; Murphy CA; Allsop JM; Foster GR; Main J; Wesnes KA; Taylor-Robinson SD. (Feb 2002). Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 35:433-439. DOI.
  • Forton DM; Allsop JM; Main J; Foster GR; Thomas HC; Taylor-Robinson SD. (7 Jul 2001). Evidence for a cerebral effect of the hepatitis C virus. Lancet. 358:38-39. DOI.
  • Wright M; Main J; Thomas HC. (Jul 2001). Treatment of chronic viral hepatitis. Antivir Chem Chemother. 12:201-212.
  • Taylor-Robinson SD; Toledano MB; Arora S; Keegan TJ; Hargreaves S; Beck A; Khan SA; Elliott P; et alThomas HC. (Jun 2001). Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut. 48:816-820.
  • Godkin A; Jeanguet N; Thursz M; Openshaw P; Thomas H. (May 2001). Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. Eur J Immunol. 31:1438-1446. DOI.
  • Forton D; Murphy C; Allsop J; Main J; Foster GR; Thomas HC; Taylor-Robinson SD. (1 Apr 2001). Correlation between neuropsychometric scores and cerebral proton magnetic resonance spectroscopy (1H-MRS) in chronic hepatitis C infection. JOURNAL OF HEPATOLOGY. 34:160-160. Author weblink DOI.
  • Thomas HC; Kapadia RD; Wells GI; Gresham AM; Sutton D; Solleveld HA; Sarkar SK; Dillon SB; et alTal-Singer R. (Apr 2001). Differences in pathogenicity of herpes simplex virus serotypes 1 and 2 may be observed by histopathology and high-resolution magnetic resonance imaging in a murine encephalitis model. J Neurovirol. 7:105-116. DOI.
  • Patel N; Blomley MJ; Cosgrove DO; Harvey CJ; Thomas HC; Taylor-Robinson SD. (1 Apr 2001). Liver vascular transit times measured after ultrasound contrast injection: A measure of diffuse liver disease?. JOURNAL OF HEPATOLOGY. 34:225-225. Author weblink DOI.
  • Wright M; Thomas HC; Goldin R; Thursz M. (1 Apr 2001). Polymorphism of the matrix metalloproteinase 1 gene and rate of liver fibrosis in chronic hepatitis C infection M. JOURNAL OF HEPATOLOGY. 34:89-89. Author weblink DOI.
  • Thursz MR; Zhang L; Frodsham A; Dumpis U; Chiaramonte M; Venturi-Pasini C; Lobello S; Hill AV; et alThomas HC. (1 Apr 2001). Polymorphisms in the IL-10 ligand and the IL-10 receptor beta chain influence susceptibility to persistent HBV infection. JOURNAL OF HEPATOLOGY. 34:14-14. Author weblink DOI.
  • Hoare J; Botto M; Thomas HC; McGarvey MJ. (1 Apr 2001). The inactivation of baculovirus vectors by the innate immune system. JOURNAL OF HEPATOLOGY. 34:222-222. Author weblink DOI.
  • Forton DM; Hargarden N; Thomas HC; Taylor-Robinson SD. (1 Mar 2001). Correlation between cerebral proton magnetic resonance spectroscopy (H-1 MRS) and neuropsychometric abnormalities in patients with chronic hepatitis C (HCV) infection. GUT. 48:A66-A67. Author weblink.
  • Seddigh-Tonekaboni S; Lim WL; Young B; Hou JL; Waters J; Luo KX; Thomas HC; Karayiannis P. (Mar 2001). Hepatitis B surface antigen variants in vaccinees, blood donors and an interferon-treated patient. J Viral Hepat. 8:154-158.
  • Patel N; Forton DM; Hamilton G; Coutts GA; Thomas HC; Taylor-Robinson SD. (1 Mar 2001). Intracellular pH of the brain in chronic hepatic encephalopathy (HE): A P-31 MR spectroscopy (MRS) study. GUT. 48:A22-A23. Author weblink.
  • Khan SA; Taylor-Robinson SD; Toledano MB; Elliott P; Thomas HC. (1 Mar 2001). Worldwide trends in mortality rates for hepatobiliary and pancreatic tumours, 1979-1997. GUT. 48:A103-A103. Author weblink.
  • Thomas HC. (Jan 2001). HCV in healthcare workers: a lightning strike. Gut. 48:8-9.
  • Kumar U; Tuthill T; Thomas HC; Monjardino J. (Nov 2000). Sequence, expression and reconstitution of an HCV genome from a British isolate derived from a single blood donation. J Viral Hepat. 7:459-465.
  • Khan SA; Taylor-Robinson SD; Toledano MB; Beck A; Elliott P; Thomas HC. (1 Oct 2000). Comparison of trends in mortality rates rates for primary liver tumours worldwide 1979-1997. HEPATOLOGY. 32:228A-228A. Author weblink.
  • Zhang L; Thursz MR; Frodsham A; Chiaramonte M; Dumpis U; Lobello S; Venturi-Pasini C; Whittle H; et alGraves M; Best S; Thomas HC; Hill AV. (1 Oct 2000). Identification of a gene for chronic hepatitis B virus infection by genome-wide linkage analysis family-based association studies. HEPATOLOGY. 32:392A-392A. Author weblink.
  • Forton DM; Taylor-Robinson SD; Karayiannis P; Thomas HC. (1 Oct 2000). Identification of brain-specific quasispecies variants of hepatitis C virus (HCV) consistent with viral replication in the central nervous system. HEPATOLOGY. 32:269A-269A. Author weblink.
  • Godkin AJ; Thursz M; Openshaw P; Thomas HC. (1 Oct 2000). Identification of HLA-DR11-restricted CD4+T cell epitopes derived from hepatitis C virus. HEPATOLOGY. 32:271A-271A. Author weblink.
  • Patel N; Forton DM; Coutts GA; Thomas HC; Taylor-Robinson SD. (Sep 2000). Intracellular pH measurements of the whole head and the basal ganglia in chronic liver disease: a phosphorus-31 MR spectroscopy study. Metab Brain Dis. 15:223-240.
  • Wright M; Main J; Thomas HC. (Jul 2000). Drug-resistant viral hepatitis. J Infect. 41:1-4. DOI.
  • Pradat P; Chossegros P; Bailly F; Pontisso P; Saracco G; Sauleda S; Thursz M; Tillmann H; et alVlassopoulou H; Alberti A; Braconier JH; Esteban JI; Hadziyannis S; Manns M; Rizzetto M; Thomas HC; Trepo C. (1 May 2000). Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. JOURNAL OF VIRAL HEPATITIS. 7:203-210. Author weblink.
  • Khan SA; Taylor-Robinson SD; Toledano MB; Arora S; Hargreaves S; Beck A; Elliott P; Thomas HC. (1 Apr 2000). Increase in mortality rates for intrahepatic cholangiocarcinoma in England & Wales 1968-1996. GUT. 46:A74-A74. Author weblink.
  • Foster GR; Thomas HC. (Apr 2000). Therapeutic options for HCV--management of the infected individual. Baillieres Best Pract Res Clin Gastroenterol. 14:255-264.
  • Seddigh-Tonekaboni S; Waters JA; Jeffers S; Gehrke R; Ofenloch B; Horsch A; Hess G; Thomas HC; et alKarayiannis P. (Feb 2000). Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol. 60:113-121.
  • Khan SA; Taylor-Robinson SD; Toledano M; Elliott P; Beck A; Thomas HC. (1 Jan 2000). Increase in mortality rates for intrahepatic cholangiocarcinoma in England & Wales 1968-1996. JOURNAL OF HEPATOLOGY. 32:117-117. Author weblink DOI.
  • Forton DM; Hargarden N; Thomas HC; Taylor-Robinson SD. (1 Jan 2000). Proton cerebral magnetic resonance spectroscopy and neuropsychometric abnormalities in patients with chronic hepatitis C infection. JOURNAL OF HEPATOLOGY. 32:30-30. DOI.
  • Wright M; Thomas HC; Goldin R; Chatterton C; Thursz MR. (1 Jan 2000). Tissue inhibitor of metalloproteinase 1 gene polymorphism and rate of liver fibrosis in chronic hepatitis C infection. JOURNAL OF HEPATOLOGY. 32:81-81. Author weblink DOI.
  • Thursz M; Yallop R; Goldin R; Trepo C; Thomas HC. (18 Dec 1999). Influence of MHC class II genotype on outcome of infection with hepatitis C virus. LANCET. 354:2119-2124. Author weblink DOI.
  • Thursz M; Yallop R; Goldin R; Trepo C; Thomas HC. (18 Dec 1999). Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet. 354:2119-2124.
  • Paterson M; Laxton CD; Thomas HC; Ackrill AM; Foster GR. (Nov 1999). Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology. 117:1187-1197.
  • Taylor-Robinson SD; Thomas HC; Arora S; Hargreaves S. (4 Sep 1999). Increased mortality from liver cancer in England and Wales is not related to hepatitis C. BRITISH MEDICAL JOURNAL. 319:640-640. Author weblink.
  • de Jode MG; Lamb GM; Thomas HC; Taylor-Robinson SD; Gedroyc WM. (Aug 1999). MRI guidance of infra-red laser liver tumour ablations, utilising an open MRI configuration system: technique and early progress. J Hepatol. 31:347-353.
  • Zampino R; Pickering J; Iqbal M; Gaud U; Thomas HC; Karayiannis P. (May 1999). Hepatitis G virus/GBV-C persistence: absence of hypervariable E2 region and genetic analysis of viral quasispecies in serum and lymphocytes. J Viral Hepat. 6:209-218.
  • Thomas HC; Török ME; Foster GR. (Apr 1999). Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alfa therapy. Hepatology. 29:1333-1334. DOI.
  • Horsmans Y; Karayiannis P; Christophe JL; Pickering JM; Debauche C; Cornu C; Rahier J; Hess G; et alThomas HC; Geubel AP. (1 Feb 1999). Severe exacerbation of liver disease during pregnancy in a thalassemic GBV-C/HGV-positive patient and neonatal hepatitis in offspring. JOURNAL OF MEDICAL VIROLOGY. 57:122-125. Author weblink DOI.
  • Thomas HC; Torok ME; Forton DM; Taylor-Robinson SD. (1 Jan 1999). Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. JOURNAL OF HEPATOLOGY. 31:152-159. Author weblink DOI.
  • Thomas HC. (Nov 1998). Mechanism of emergence of hepatitis B virus escape variants: approaches to prevention. J Viral Hepat. 5 Suppl 2:31-36.
  • Main J; McCarron B; Thomas HC. (Nov 1998). Treatment of chronic viral hepatitis. Antivir Chem Chemother. 9:449-460.
  • Schulte-Frohlinde E; Fischer G; Seidler B; Wlodzimirez M; Classen M; Thomas HC; Foster GR. (1 Oct 1998). Host factors in chronic hepatitis B: Results of a microsatellite-analysis of a region adjacent to the interferon alpha-gene-cluster. HEPATOLOGY. 28:723A-723A. Author weblink.
  • Schulte-Frohlinde E; Fischer G; Seidler B; Wlodzimirez M; Classen M; Thomas HC; Foster GR. (1 Oct 1998). Host factors in chronic hepatitis B: Results of a microsatellite-analysis of a region adjacent to the interferon alpha-gene-cluster. HEPATOLOGY. 28:720A-720A. Author weblink.
  • Taylor-Robinson SD; Arora S; Hargreaves S; Thomas HC. (1 Oct 1998). Increase in cholangiocarcinoma in England and Wales 1979-1995. HEPATOLOGY. 28:242A-242A. Author weblink.
  • McCarron B; Main J; Thomas HC. (Oct 1998). Molecular and therapeutic advances in the management of chronic hepatitis B and C. Curr Opin Infect Dis. 11:555-564.
  • Gulati VK; Waters J; Thomas HC. (1 Oct 1998). Production of IFN gamma by different subsets of peripheral blood mononuclear cells from late acute hepatitis B patients, persistently infected HBV carriers and healthy volunteers. HEPATOLOGY. 28:722A-722A. Author weblink.
  • Paterson M; Laxton CD; Sully R; Thomas HC; Ackrill A; Foster GR. (1 Oct 1998). The non-structural 5A protein of the hepatitis C virus blocks the anti-viral effects triggered by IFN-alpha. HEPATOLOGY. 28:370A-370A. Author weblink.
  • Honkoop P; de Man RA; Niesters HGM; Main J; Nevens F; Thomas HC; Fevery J; Tyrrell DL; et alSchalm SW. (1 Sep 1998). Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. JOURNAL OF VIRAL HEPATITIS. 5:307-312. Author weblink DOI.
  • Karayiannis P; Pickering J; Zampino R; Thomas HC. (15 Jul 1998). Natural history and molecular biology of hepatitis G virus/GB virus C. Clin Diagn Virol. 10:103-111.
  • Waters JA; Bailey C; Love C; Thomas HC. (Jan 1998). A study of the antigenicity and immunogenicity of a new hepatitis B vaccine using a panel of monoclonal antibodies. J Med Virol. 54:1-6.
  • Foster GR; Goldin RD; Thomas HC. (Jan 1998). Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 27:209-212. DOI.
  • Booth JC; Kumar U; Webster D; Monjardino J; Thomas HC. (Jan 1998). Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology. 27:223-227. DOI.
  • Karayiannis P; Brind AM; Pickering J; Mathew J; Burt AD; Hess G; Bassendine MF; Thomas HC. (Jan 1998). Hepatitis G virus does not cause significant liver disease after liver transplantation. J Viral Hepat. 5:35-42.
  • Thursz MR; Thomas HC; Greenwood BM; Hill AVS. (1 Jan 1998). Heterozygote advantage for HLA class-II type in hepatitis B virus infection (vol 17, pg 10, 1997). NATURE GENETICS. 18:88-88.
  • Aiba N; McGarvey MJ; Waters J; Hadziyannis SJ; Thomas HC; Karayiannis P. (Nov 1997). The precore sequence of hepatitis B virus is required for nuclear localization of the core protein. Hepatology. 26:1311-1317. DOI.
  • TaylorRobinson SD; Foster GR; Arora S; Hargreaves S; Thomas HC. (18 Oct 1997). Increase in primary liver cancer in the UK, 1979-94. LANCET. 350:1142-1143. Author weblink DOI.
  • Thursz MR; Thomas HC; Greenwood BM; Hill AVS. (1 Sep 1997). Heterozygote advantage for HLA class-II type in hepatitis B virus infection. NATURE GENETICS. 17:11-12. Author weblink DOI.
  • Foster GR; Goldin RD; Main J; Murray-Lyon I; Hargreaves S; Thomas HC. (23 Aug 1997). Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ. 315:453-458.
  • Shanmuganathan S; Waters JA; Karayiannis P; Thursz M; Thomas HC. (Jun 1997). Mapping of the cellular immune responses to woodchuck hepatitis core antigen epitopes in chronically infected woodchucks. J Med Virol. 52:128-135.
  • Booth JC; Foster GR; Levine T; Thomas HC; Goldin RD. (Jun 1997). The relationship of histology to genotype in chronic HCV infection. Liver. 17:144-151.
  • Pickering JM; Thomas HC; Karayiannis P. (May 1997). Predicted secondary structure of the hepatitis G virus and GB virus-A 5'untranslated regions consistent with an internal ribosome entry site. J Viral Hepat. 4:175-184.
  • Alexopoulou A; Karayiannis P; Hadziyannis SJ; Aiba N; Thomas HC. (Apr 1997). Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species. J Hepatol. 26:748-753.
  • Thursz M; Mantafounis D; Yallop R; Thomas HC; Teare J. (1 Apr 1997). Severe alcoholic liver disease is associated with the haemochromatosis gene mutant. GASTROENTEROLOGY. 112:A1401-A1401. Author weblink.
  • Karayiannis P; Pickering J; Chiaramonte M; Thomas HC. (29 Mar 1997). Hepatitis G virus infection. LANCET. 349:954-954. Author weblink DOI.
  • Yuan ZH; Kumar U; Thomas HC; Wen YM; Monjardino J. (6 Mar 1997). Expression, purification, and partial characterization of HCV RNA polymerase. Biochem Biophys Res Commun. 232:231-235. DOI.
  • Karayiannis P; Thomas HC. (Mar 1997). Hepatitis G virus: identification, prevalence and unanswered questions. Gut. 40:294-296.
  • Thomas HC; Waters JA. (Feb 1997). Future approaches to treatment of chronic hepatitis B and hepatitis C infection. J VIRAL HEPATITIS. 4:92-97.
  • Thomas HC; Thursz MR. (Feb 1997). Immunogenetics of hepatitis B virus infection. J VIRAL HEPATITIS. 4:98-100.
  • Karayiannis P; Thomas HC. (1997). Current status of hepatitis G virus (GBV-C) in transfusion: is it relevant?. Vox Sang. 73:63-69.
  • Pickering JM; Thomas HC; Karayiannis P. (Jan 1997). Genetic diversity between hepatitis G virus isolates: analysis of nucleotide variation in the NS-3 and putative 'core' peptide genes. J Gen Virol. 78 ( Pt 1):53-60.
  • Karayiannis P; Hadziyannis SJ; Kim J; Pickering JM; Piatak M; Hess G; Yun A; McGarvey MJ; et alWages J; Thomas HC. (Jan 1997). Hepatitis G virus infection: clinical characteristics and response to interferon. J Viral Hepat. 4:37-44.
  • Thursz MR; Thomas HC. (1997). Host factors in chronic viral hepatitis. Semin Liver Dis. 17:345-350. DOI.
  • Thomas HC; Pickering J; Karayiannis P. (Jan 1997). Identification, prevalence and aspects of molecular biology of hepatitis G virus. J VIRAL HEPATITIS. 4:51-54.
  • Foster GR; Rodrigues O; Ghouze F; Schulte-Frohlinde E; Testa D; Liao MJ; Stark GR; Leadbeater L; et alThomas HC. (Dec 1996). Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J Interferon Cytokine Res. 16:1027-1033.
  • Thomas HC; Foster GR; Sumiya M; McIntosh D; Jack DL; Turner MW; Summerfield JA. (23 Nov 1996). Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection. Lancet. 348:1417-1419.
  • Goldin RD; Patel NK; Thomas HC. (Oct 1996). Hepatitis C and bile duct loss. J Clin Pathol. 49:836-838.
  • Booth JCL; Waters J; Thomas HC. (1 Oct 1996). Hepatitis C virus is present in CD8+ve T lymphocytes, B lymphocytes and monocytes but not in CD4+ve T lymphocytes in persistently infected patients. HEPATOLOGY. 24:1002-1002. Author weblink.
  • Thursz MR; Mantafounis D; Yallop RM; Hewitt PE; Thomas HC. (1 Oct 1996). MHC class II and self limiting hepatitis C virus infection. HEPATOLOGY. 24:1024-1024. Author weblink.
  • McCarron B; Main J; Thomas HC. (1 Oct 1996). Viral hepatitis, new viruses and therapies. CURRENT OPINION IN INFECTIOUS DISEASES. 9:359-364. Author weblink DOI.
  • Karayiannis P; Thomas HC. (4 Sep 1996). Hepatitis G virus: identification and prevalence. Br J Hosp Med. 56:238-240.
  • Carman WF; Trautwein C; vanDeursen FJ; Colman K; Dornan E; McIntyre G; Waters J; Kliem V; et alMuller R; Thomas HC; Mannis MP. (1 Sep 1996). Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. HEPATOLOGY. 24:489-493. Author weblink DOI.
  • Main J; Brown JL; Howells C; Galassini R; Crossey M; Karayiannis P; Georgiou P; Atkinson G; et alThomas HC. (Jul 1996). A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat. 3:211-215.
  • Booth JC; Thomas HC. (Jul 1996). Pathogenesis of chronic hepatitis C and associated clinical manifestations. Baillieres Clin Gastroenterol. 10:257-274.
  • Alexopoulou A; Karayiannis P; Hadziyannis SJ; Hou J; Pickering J; Luo K; Thomas HC. (Jul 1996). Whole genome analysis of hepatitis B virus from four cases of fulminant hepatitis: genetic variability and its potential role in disease pathogenicity. J Viral Hepat. 3:173-181.
  • Nowak MA; Bonhoeffer S; Hill AM; Boehme R; Thomas HC; McDade H. (30 Apr 1996). Viral dynamics in hepatitis B virus infection. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 93:4398-4402. Author weblink DOI.
  • Goldin RD; Levine TS; Foster GR; Thomas HC. (Mar 1996). Granulomas and hepatitis C. Histopathology. 28:265-267.
  • McGarvey MJ; Goldin RD; Karayiannis P; Thomas HC. (Mar 1996). The expression of hepatitis B virus polymerase in hepatocytes during chronic HBV infection. J Viral Hepat. 3:67-73.
  • Thomas HC; Booth J; Brown J. (1 Jan 1996). Pathophysiology and treatment of hepatitis C. DRUGS. 52:1-7. Author weblink DOI.
  • Karayiannis P; Alexopoulou A; Hadziyannis S; Thursz M; Watts R; Seito S; Thomas HC. (Dec 1995). Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection: importance of host factors. Hepatology. 22:1628-1634.
  • Waters JA; O'Rourke S; Schlict HJ; Thomas HC. (Nov 1995). Cytotoxic T cell responses in patients with chronic hepatitis B virus infection undergoing HBe antigen/antibody seroconversion. Clin Exp Immunol. 102:314-319.
  • FATTOVICH G; MCINTYRE G; THURSZ M; COLMAN K; GIULIANO G; ALBERTI A; THOMAS HC; CARMAN WF. (1 Nov 1995). HEPATITIS-B VIRUS PRECORE CORE VARIATION AND INTERFERON THERAPY. HEPATOLOGY. 22:1355-1362. Author weblink DOI.
  • Karayiannis P; O'Rourke S; Watts R; Waters J; Hill V; Carman WF; Thomas HC. (Nov 1995). Recombinant vaccinia viruses expressing hepatitis A virus structural polypeptides: detection of an anti-VP0 response in convalescent-phase sera. Clin Diagn Lab Immunol. 2:708-711.
  • THOMAS HC; FOSTER GR; SUMIYA M; MCINTOSH D; TURNER MW; SUMMERFIELD JA. (1 Oct 1995). CHRONIC HEPATITIS-B VIRUS-INFECTION IS ASSOCIATED WITH MUTATIONS IN THE MANNOSE-BINDING PROTEIN GENE. HEPATOLOGY. 22:627-627. Author weblink.
  • Booth JC; Brown JL; Thomas HC. (Oct 1995). The management of chronic hepatitis C virus infection. Gut. 37:449-454.
  • Niu J; Kumar U; Monjardino J; Goldin R; Rosin D; Thomas HC. (Sep 1995). Hepatitis C virus replication in hepatocellular carcinoma. J Clin Pathol. 48:880-882.
  • Thursz MR; Kwiatkowski D; Allsopp CE; Greenwood BM; Thomas HC; Hill AV. (20 Apr 1995). Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med. 332:1065-1069. DOI.
  • Thursz MR; Kwiatkowski D; Torok ME; Allsopp CE; Greenwood BM; Whittle HC; Thomas HC; Hill AV. (Apr 1995). Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. Nat Med. 1:374-375.
  • Booth JC; Goldin RD; Brown JL; Karayiannis P; Thomas HC. (Apr 1995). Fibrosing cholestatic hepatitis in a renal transplant recipient associated with the hepatitis B virus precore mutant. J Hepatol. 22:500-503.
  • Booth JC; Foster GR; Kumar U; Galassini R; Goldin RD; Brown JL; Thomas HC. (Mar 1995). Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha. Gut. 36:427-432.
  • Teare JP; Booth JC; Brown JL; Martin J; Thomas HC. (Mar 1995). Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol. 7:275-277.
  • Hou J; Karayiannis P; Waters J; Luo K; Liang C; Thomas HC. (Feb 1995). A unique insertion in the S gene of surface antigen--negative hepatitis B virus Chinese carriers. Hepatology. 21:273-278.
  • CARMAN WF; THURSZ M; HADZIYANNIS S; MCINTYRE G; COLMAN K; GIOUSTOZ A; FATTOVICH G; ALBERTI A; et alTHOMAS HC. (1 Jan 1995). HEPATITIS-B E-ANTIGEN NEGATIVE CHRONIC ACTIVE HEPATITIS - HEPATITIS-B VIRUS CORE MUTATIONS OCCUR PREDOMINANTLY IN KNOWN ANTIGENIC DETERMINANTS. JOURNAL OF VIRAL HEPATITIS. 2:77-84. Author weblink DOI.
  • FEITELSON MA; DUAN LX; GUO J; HORIIKE N; MCINTYRE G; BLUMBERG BS; THOMAS HC; CARMAN W. (1 Jan 1995). PRECORE AND X-REGION MUTANTS IN HEPATITIS-B VIRUS-INFECTIONS AMONG RENAL DIALYSIS PATIENTS. JOURNAL OF VIRAL HEPATITIS. 2:19-31. Author weblink DOI.
  • Thomas HC. (1995). The emergence of envelope and precore/core variants of hepatitis B virus: the potential role of antibody selection. J Hepatol. 22:1-8.
  • Thomas HC; Carman WF. (Sep 1994). Envelope and precore/core variants of hepatitis B virus. Gastroenterol Clin North Am. 23:499-514.
  • Foster GR; Thomas HC. (Jul 1994). Effects of hepatitis B and hepatitis C virus replication on the actions of interferon. Antiviral Res. 24:131-136.
  • McNair AN; Cheng D; Monjardino J; Thomas HC; Kerr IM. (Jun 1994). Hepatitis delta virus replication in vitro is not affected by interferon-alpha or -gamma despite intact cellular responses to interferon and dsRNA. J Gen Virol. 75 ( Pt 6):1371-1378.
  • MCNAIR ANB; CHENG D; MONJARDINO J; THOMAS HC; KERR IM. (1 Jun 1994). HEPATITIS-DELTA VIRUS-REPLICATION IN-VITRO IS NOT AFFECTED BY INTERFERON-ALPHA OR INTERFERON-GAMMA DESPITE INTACT CELLULAR-RESPONSES TO INTERFERON AND DSRNA. JOURNAL OF GENERAL VIROLOGY. 75:1371-1378. DOI.
  • BOOTH JCL; FOSTER GR; KUMAR U; GALASSINI R; GOLDIN RD; BROWN JL; THOMAS HC. (1 Apr 1994). CHRONIC HEPATITIS-C VIRUS-INFECTIONS - PREDICTIVE VALUE OF GENOTYPE ON DISEASE PROGRESSION AND RESPONSE TO INTERFERON-ALPHA. GASTROENTEROLOGY. 106:A868-A868. Author weblink.
  • Kumar U; Monjardino J; Thomas HC. (Apr 1994). Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology. 106:1072-1075.
  • Kumar U; Thomas HC; Monjardino J. (Apr 1994). Serum HCV RNA levels in chronic HCV hepatitis measured by quantitative PCR assay; correlation with serum AST. J Virol Methods. 47:95-102.
  • MCNAIR ANB; CHENG D; MONJARDINO J; THOMAS HC; KERR IM. (1 Apr 1994). THE HEPATITIS-DELTA VIRUS DOES NOT AFFECT THE ANTIVIRAL ACTIONS OF INTERFERON. GASTROENTEROLOGY. 106:A941-A941. Author weblink.
  • Taylor M; Goldin RD; Ladva S; Scheuer PJ; Thomas HC. (Mar 1994). In situ hybridization studies of hepatitis A viral RNA in patients with acute hepatitis A. J Hepatol. 20:380-387.
  • Thomas HC; Lok AS; Carreño V; Farrell G; Tanno H; Perez V; Dusheiko GM; Cooksley G; et alRyff JC. (1994). Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group. J Viral Hepat. 1:139-148.
  • JACYNA MR; THOMAS HC. (1 Dec 1993). TREATMENT OF HEPATITIS-C. REVIEWS IN MEDICAL VIROLOGY. 3:201-207. Author weblink DOI.
  • Cohen H; Hunt JB; Dixit M; Kanwar S; Thomas HC. (Nov 1993). Decreased contact factor mediated fibrinolysis in cirrhosis. Br J Haematol. 85:542-545.
  • Karayiannis P; Saldanha J; Jackson AM; Luther S; Goldin R; Monjardino J; Thomas HC. (Nov 1993). Partial control of hepatitis delta virus superinfection by immunisation of woodchucks (Marmota monax) with hepatitis delta antigen expressed by a recombinant vaccinia or baculovirus. J Med Virol. 41:210-214.
  • CARMAN WF; THOMAS HC. (1 Jan 1993). IMPLICATIONS OF GENETIC-VARIATION ON THE PATHOGENESIS OF HEPATITIS-B VIRUS-INFECTION. ARCHIVES OF VIROLOGY. 143-154. Author weblink.
  • Hunt JB; Appleyard M; Thursz M; Carey PD; Guillou PJ; Thomas HC. (Jun 1993). Intraperitoneal haemorrhage from anterior abdominal wall varices. Postgrad Med J. 69:490-493.
  • Brook MG; Main J; Yap I; Chan G; Karayiannis P; Crossey M; Thomas HC. (Jun 1993). Short report: prednisolone withdrawal followed by lymphoblastoid interferon in the therapy of adult patients with presumed childhood-acquired chronic hepatitis B virus infection. Aliment Pharmacol Ther. 7:331-336.
  • Foster GR; Goldin RD; Hay A; McGarvey MJ; Stark GR; Thomas HC. (May 1993). Expression of the terminal protein of hepatitis B virus is associated with failure to respond to interferon therapy. Hepatology. 17:757-762.
  • Kumar U; Brown J; Monjardino J; Thomas HC. (Mar 1993). Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J Infect Dis. 167:726-730.
  • Thomas HC; Karayiannis P; Monjardino J; McNair A. (1993). Hepatitis delta virus and the host response: current status and future perspectives. Prog Clin Biol Res. 382:431-435.
  • McNair AN; Monjardino J; Cheng D; Thomas HC. (1993). Hepatitis delta virus and the interferon system. Prog Clin Biol Res. 382:161-164.
  • Karayiannis P; Saldanha J; Monjardino J; Jackson A; Luther S; Thomas HC. (1993). Immunisation of woodchucks with hepatitis delta antigen expressed by recombinant vaccinia and baculoviruses, controls HDV superinfection. Prog Clin Biol Res. 382:193-199.
  • Foster GR; Thomas HC. (Jan 1993). Recent advances in the molecular biology of hepatitis B virus: mutant virus and the host response. Gut. 34:1-3.
  • Waters JA; Kennedy M; Voet P; Hauser P; Petre J; Carman W; Thomas HC. (Dec 1992). Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest. 90:2543-2547. DOI.
  • Main J; Jacyna MR; Thomas HC. (11 Sep 1992). The diagnosis and management of viral hepatitis. Commun Dis Rep CDR Rev. 2:R117-R120.
  • Taylor GM; Goldin RD; Karayiannis P; Thomas HC. (Sep 1992). In situ hybridization studies in hepatitis A infection. Hepatology. 16:642-648.
  • McNair AN; Main J; Thomas HC. (May 1992). Interactions of the human immunodeficiency virus and the hepatotropic viruses. Semin Liver Dis. 12:188-196. DOI.
  • Saldanha JA; Qiu H; Thomas HC; Monjardino J. (May 1992). Mapping of 5' ends of virion-derived HBV DNA. Virology. 188:358-361.
  • Karayiannis P; Goldin R; Luther S; Carman WF; Monjardino J; Thomas HC. (Apr 1992). Effect of cyclosporin-A in woodchucks with chronic hepatitis delta virus infection. J Med Virol. 36:316-321.
  • CARMAN WF; THOMAS HC. (1 Feb 1992). GENETIC-VARIATION IN HEPATITIS-B-VIRUS. GASTROENTEROLOGY. 102:711-719. Author weblink.
  • Brown J; Dourakis S; Karayiannis P; Goldin R; Chiba J; Ohba H; Miyamura T; Thomas HC. (Feb 1992). Seroprevalence of hepatitis C virus nucleocapsid antibodies in patients with cryptogenic chronic liver disease. Hepatology. 15:175-179.
  • Waters JA; Brown SE; Steward MW; Howard CR; Thomas HC. (Jan 1992). Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res. 22:1-12.
  • Thomas HC. (Jan 1992). Does the precore mutant of HBV cause fulminant hepatitis?. Hepatology. 15:166-167.
  • HUNT JB; COHEN H; DIXIT M; KANWAR S; THOMAS HC. (1 Jan 1992). INTRINSIC FIBRINOLYSIS IS DECREASED IN CIRRHOSIS. GUT. 33:S8-S8. Author weblink.
  • Carman WF; Ferrao M; Lok AS; Ma OC; Lai CL; Thomas HC. (Jan 1992). Precore sequence variation in Chinese isolates of hepatitis B virus. J Infect Dis. 165:127-133.
  • Brown JL; Carman WF; Thomas HC. (Jan 1992). The clinical significance of molecular variation within the hepatitis B virus genome. Hepatology. 15:144-148.
  • BROWN JL; CARMAN WF; THOMAS HC. (1 Jan 1992). THE CLINICAL-SIGNIFICANCE OF MOLECULAR VARIATION WITHIN THE HEPATITIS-B VIRUS GENOME. HEPATOLOGY. 15:141-148. Author weblink.
  • Thomas HC; Carman WF. (1992). The host immune response may be responsible for selection of envelope and precore/core variants of HBV. Prog Liver Dis. 10:239-251.
  • Karayiannis P; O'Rourke S; McGarvey MJ; Luther S; Waters J; Goldin R; Thomas HC. (Sep 1991). A recombinant vaccinia virus expressing hepatitis A virus structural polypeptides: characterization and demonstration of protective immunogenicity. J Gen Virol. 72 ( Pt 9):2167-2172.
  • KARAYIANNIS P; OROURKE S; MCGARVEY MJ; LUTHER S; WATERS J; GOLDIN R; THOMAS HC. (1 Sep 1991). A RECOMBINANT VACCINIA VIRUS EXPRESSING HEPATITIS-A VIRUS STRUCTURAL POLYPEPTIDES - CHARACTERIZATION AND DEMONSTRATION OF PROTECTIVE IMMUNOGENICITY. JOURNAL OF GENERAL VIROLOGY. 72:2167-2172. Author weblink DOI.
  • Dourakis S; Karayiannis P; Goldin R; Taylor M; Monjardino J; Thomas HC. (Sep 1991). An in situ hybridization, molecular biological and immunohistochemical study of hepatitis delta virus in woodchucks. Hepatology. 14:534-539.
  • Carman WF; Fagan EA; Hadziyannis S; Karayiannis P; Tassopoulos NC; Williams R; Thomas HC. (Aug 1991). Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology. 14:219-222.
  • Monjardino J; Velosa J; Thomas HC; de Moura MC. (Jul 1991). Serum HBV DNA detected by PCR in dot blot negative HBV chronic carriers with active liver disease. J Hepatol. 13:44-48.
  • Carman WF; Dourakis S; Karayiannis P; Crossey M; Drobner R; Thomas HC. (Jun 1991). Incidence of hepatitis B viraemia, detected using the polymerase chain reaction, after successful therapy of hepatitis B virus carriers with interferon-alpha. J Med Virol. 34:114-118.
  • Foster GR; Carman WF; Thomas HC. (May 1991). Replication of hepatitis B and delta viruses: appearance of viral mutants. Semin Liver Dis. 11:121-127. DOI.
  • Foster GR; Ackrill AM; Goldin RD; Kerr IM; Thomas HC; Stark GR. (1 Apr 1991). Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A. 88:2888-2892.
  • Saldanha JA; Thomas HC; Trepo C; Monjardino JP. (1991). Cloning and expression of hepatitis delta virus RNA from human serum. Prog Clin Biol Res. 364:315-320.
  • Monjardino J; Saldanha J; Goldin R; Thomas HC. (1991). Genetically engineered molecular probes in the study of the natural history of chronic delta hepatitis. Prog Clin Biol Res. 364:197-199.
  • Karayiannis P; Saldanha J; Monjardino J; Farci P; Thomas HC. (1991). Prevention and treatment of hepatitis delta virus infection. Prog Clin Biol Res. 364:377-383.
  • Thomas HC; Carman WF. (1991). The host immune response may be responsible for selection of envelope and precore/core variants of HBV. J Hepatol. 13 Suppl 4:S108-S113.
  • Thomas HC; Karayiannis P; Brook G. (1991). Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon. J Hepatol. 13 Suppl 1:S4-S7.
  • Jacyna MR; Thomas HC. (Dec 1990). Parenterally acquired non-A non-B hepatitis ten years on: advances in diagnosis and therapy. Postgrad Med J. 66:1000-1004.
  • Karayiannis P; Saldanha J; Monjardino J; Goldin R; Main J; Luther S; Easton M; Ponzetto A; et alThomas HC. (Nov 1990). Immunization of woodchucks with recombinant hepatitis delta antigen does not protect against hepatitis delta virus infection. Hepatology. 12:1125-1128.
  • Jacyna MR; O'Neill K; Brown J; Drobner R; Karayiannis P; Thomas HC. (Oct 1990). Hepatitis C virus antibodies in subjects with and without liver disease in the United Kingdom. Q J Med. 77:1009-1012.
  • BROWN JL; CARMAN WF; THOMAS HC. (1 Sep 1990). THE HEPATITIS-B VIRUS. BAILLIERES CLINICAL GASTROENTEROLOGY. 4:721-747. Author weblink DOI.
  • Carman WF; Zanetti AR; Karayiannis P; Waters J; Manzillo G; Tanzi E; Zuckerman AJ; Thomas HC. (11 Aug 1990). Vaccine-induced escape mutant of hepatitis B virus. Lancet. 336:325-329.
  • Middleton SJ; Jacyna M; McClaren D; Robinson R; Thomas HC. (Aug 1990). Haemorrhagic pancreatitis--a cause of death in severe potassium permanganate poisoning. Postgrad Med J. 66:657-658.
  • Saldanha JA; Thomas HC; Monjardino JP. (Jul 1990). Cloning and sequencing of RNA of hepatitis delta virus isolated from human serum. J Gen Virol. 71 ( Pt 7):1603-1606.
  • Karayiannis P; Kanatakis S; Thomas HC. (May 1990). Anti-HBs response in seroconverting chronic HBV carriers following alpha-interferon treatment. J Hepatol. 10:350-352.
  • Jacyna MR; Thomas HC. (Apr 1990). Antiviral therapy: hepatitis B. Br Med Bull. 46:368-382.
  • CARMAN WF; THOMAS HC. (1 Mar 1990). HEPATITIS VIRUSES. BAILLIERES CLINICAL GASTROENTEROLOGY. 4:201-232. Author weblink DOI.
  • Goldin RD; Fish DE; Hay A; Waters JA; McGarvey MJ; Main J; Thomas HC. (Mar 1990). Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J Clin Pathol. 43:203-205.
  • Saldanha J; Homer E; Goldin R; Thomas HC; Monjardino J. (Feb 1990). Cloning and expression of an immunodominant region of the hepatitis delta antigen. J Gen Virol. 71 ( Pt 2):471-475.
  • Karayiannis P; Chitranukroh R; Fry M; Petrovic LM; Moore D; Scheuer PJ; Thomas HC. (Feb 1990). Protracted alanine aminotransferase levels in tamarins infected with hepatitis A virus. J Med Virol. 30:151-158.
  • THOMAS HC. (1 Jan 1990). LIVER IMMUNOPATHOLOGY - INTRODUCTION. SPRINGER SEMINARS IN IMMUNOPATHOLOGY. 12:1-3. Author weblink.
  • Thomas HC. (1990). The hepatitis B virus and the host response. J Hepatol. 11 Suppl 1:S83-S89.
  • Main J; Thomas HC. (1990). Treatment of chronic hepatitis B infection. Pharmacol Ther. 45:373-381.
  • Farci P; Karayiannis P; Brook MG; Smedile A; Lai ME; Balestrieri A; Saldanha JA; Monjardino J; et alGerin J; Thomas HC. (Nov 1989). Treatment of chronic hepatitis delta virus (HDV) infection with human lymphoblastoid alpha interferon. Q J Med. 73:1045-1054.
  • Brook MG; Karayiannis P; Thomas HC. (Nov 1989). Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology. 10:761-763.
  • Diggory P; Jacyna MR; Booth JC; Cook HT; Thomas HC. (Oct 1989). Gallbladder cancer presenting with Trousseau's sign in a 31-year-old man with occupational exposure to aromatic hydrocarbons. J R Soc Med. 82:631-632.
  • Carman WF; Jacyna MR; Hadziyannis S; Karayiannis P; McGarvey MJ; Makris A; Thomas HC. (9 Sep 1989). Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 2:588-591.
  • Brook MG; Chan G; Yap I; Karayiannis P; Lever AM; Jacyna M; Main J; Thomas HC. (9 Sep 1989). Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. BMJ. 299:652-656.
  • Brook MG; McDonald JA; Karayiannis P; Caruso L; Forster G; Harris JR; Thomas HC. (Aug 1989). Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut. 30:1116-1122.
  • Chen G; Karayiannis P; McGarvey MJ; Lever AM; McDonald JA; Scully LJ; Kanatakis S; Thomas HC. (Aug 1989). Subclasses of antibodies to hepatitis B core antigen in chronic HBV infection: changes during treatment with alpha interferons and predictors of response. Gut. 30:1123-1128.
  • KUIJPERS L; KOENS M; MURRAYLYON I; COLEMAN JC; KARAYIANNIS P; THOMAS HC; ZANETTI A; CARGNEL A; et alHARRISON TJ; ZUCKERMAN AJ. (1 May 1989). PRE-S PROTEINS IN HEPATITIS-B. JOURNAL OF MEDICAL VIROLOGY. 28:47-51. Author weblink DOI.
  • BROOK MG; PETROVIC L; MCDONALD JA; SCHEUER PJ; THOMAS HC. (1 Mar 1989). HISTOLOGICAL IMPROVEMENT AFTER ANTI-VIRAL TREATMENT FOR CHRONIC HEPATITIS-B VIRUS-INFECTION. JOURNAL OF HEPATOLOGY. 8:218-225. Author weblink DOI.
  • Karayiannis P; Petrovic LM; Fry M; Moore D; Enticott M; McGarvey MJ; Scheuer PJ; Thomas HC. (Feb 1989). Studies of GB hepatitis agent in tamarins. Hepatology. 9:186-192.
  • Jacyna MR; Brooks MG; Loke RH; Main J; Murray-Lyon IM; Thomas HC. (14 Jan 1989). Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis. BMJ. 298:80-82.
  • Onji M; Lever AM; Saito I; Thomas HC. (Jan 1989). Defective response to interferons in cells transfected with the hepatitis B virus genome. Hepatology. 9:92-96.
  • Thomas HC; Jacyna MR; Main J. (Dec 1988). Management of non A, non B hepatitis: the problem and its treatment. Chemioterapia. 7 Suppl 3:30-34.
  • Farci P; Karayiannis P; Lai ME; Marongiu F; Orgiana G; Balestrieri A; Thomas HC. (Nov 1988). Acute and chronic hepatitis delta virus infection: direct or indirect effect on hepatitis B virus replication?. J Med Virol. 26:279-288.
  • Thomas HC; Jacyna M; Waters J; Main J. (Nov 1988). Virus-host interaction in chronic hepatitis B virus infection. Semin Liver Dis. 8:342-349. DOI.
  • Thomas HC. (29 Aug 1988). Hepatitis B viral infection. Am J Med. 85:135-140.
  • JACYNA MR; BROOKS G; LOKE RHT; CROSSEY M; MURRAYLYON IM; THOMAS HC. (1 Aug 1988). A CONTROLLED-STUDY OF LYMPHOBLASTOID INTERFERON IN CHRONIC NON-A, NON-B HEPATITIS - SHORT-TERM RESULTS. JOURNAL OF HEPATOLOGY. 7:P3-P3. Author weblink.
  • Thomas HC. (Oct 1987). Non-A, non-B hepatitis. Q J Med. 65:793-798.
  • WIEDMANN KH; TREJDOSIEWICZ LK; SOUTHGATE J; THOMAS HC. (1 May 1987). HUMAN HEPATOCELLULAR-CARCINOMA - CROSS-REACTIVE AND IDIOTYPIC ANTIGENS ASSOCIATED WITH MALIGNANT TRANSFORMATION OF EPITHELIAL-CELLS. HEPATOLOGY. 7:543-550. DOI.
  • DUNK AA; SCOTT SC; JOHNSON PJ; MELIA W; LOK ASF; MURRAYLYON I; WILLIAMS R; THOMAS HC. (1 Jan 1985). MITOZANTRONE AS SINGLE AGENT THERAPY IN HEPATOCELLULAR-CARCINOMA - A PHASE-II STUDY. JOURNAL OF HEPATOLOGY. 1:395-404. Author weblink DOI.
  • DUNK AA; SCOTT SC; JOHNSON PJ; MURRAYLYON I; WILLIAMS R; THOMAS HC. (1 Jan 1984). MITOXANTRONE AS SINGLE AGENT THERAPY IN PRIMARY HEPATOCELLULAR-CARCINOMA. GUT. 25:1131-1131. Author weblink.
  • BASSENDINE MF; WRIGHT NA; THOMAS HC; SHERLOCK S. (1 Jan 1983). GROWTH-CHARACTERISTICS OF ALPHA-FETOPROTEIN-SECRETING HUMAN HEPATOCELLULAR-CARCINOMA IN ATHYMIC (NUDE) MICE. CLINICAL SCIENCE. 64:643-648. Author weblink.
  • BASSENDINE MF; WRIGHT NA; THOMAS HC; SHERLOCK S. (1 Jan 1980). CYTOKINETIC STUDIES OF ALPHAFETOPROTEIN AND HEPATITIS-B SURFACE-ANTIGEN PRODUCING HUMAN PRIMARY LIVER-CELL CANCER IN NUDE(ATHYMIC)MICE. CLINICAL SCIENCE. 59:P20-P20. Author weblink.
  • LEVER AML; ONJI M; SAITO I; THOMAS HC. (1 Jan 1987). REDUCED SENSITIVITY TO INTERFERON IN CELLS CONTAINING THE HEPATITIS-B VIRUS GENOME. CLINICAL SCIENCE. 73:P30-P30. Author weblink.
  • Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, Bassendine M, Main J, Thomas H.; grieve R; Roberts J; Wright M; Sweeting M; DeAngelis D; Rosenberg W; Bassendine M; et alMain J; Thomas H. Related Articles, Links Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut. 2006 Sep;55(9):1332-8. Gut. 55:1332-1338.

Books

  • Thomas HC,; Lemon.S; Zuckerman A. Thomas HC (ed); Lemon S (ed); Zuckerman A (ed). Viral Hepatitis. Third Edition:3-876. Blackwell Publishing, Oxford, UK (2005).
  • Thomas HC; Lemon S; Zuckerman AJ. Thomas HC (ed); Lemon S (ed); Zuckerman AJ (ed). Viral Hepatitis. Third Edition:1-876. Blackwell Publishing, Oxford; UK (2005).

Chapters in books

  • Gess M; Forton DM; Thomas HC. Affective and cognitive disorders in hepatitis C infection: are they real and what are the mechanisms?. In Clinical Dilemmas in Viral Liver Disease. 19-23. Foster G (ed); Reddy KR (ed). Wiley-Blackwell, Chichester (2010).
  • Forton DM; Allsop J; Thomas HC; Taylor-Robinson SD. Central nervous system involvement in hepatitis C virus infection: What to measure?. In Hepatic Encephalopathy and Nitrogen Metabolism. 284-290. Häussinger D (ed); Kirchels G (ed); Schless F (ed). Springer Science, Dordrecht (11 Jul 2006).
  • Forton DM; Taylor-Robinson SD; Cox IJ; Thomas HC. Central nervous system complications. In Viral hepatitis. 3:482-495. Thomas HC (ed); Lemon SM (ed); Zuckerman AJ (ed). Blackwell, Oxford (2005).
  • Forton DM; Prince M; Allsop J; Patel N; Goldblatt J; Thomas HC; Bassendine M; Jones DEJ; et alTaylor-Robinson SD. Reduced pallidal magnetisation transfer ratios are associated with fatigue in pre-cirrhotic primary biliary cirrhosis. In Encephalopathy and nitrogen metabolism in liver failure. 173-176. Jones EA (ed); Meijer AJ (ed); Chamuleau RAFM (ed). Kluwer, Dordrecht (31 May 2003).
  • Forton DM; Fletcher A; Thomas HC; Taylor-Robinson SD. Does Hepatitis C Virus Affect the Brain? A proton magnetic resonance study (1H MRS). In Advances in hepatic encephalopathy & metabolism in liver disease. 325-329. Bozkaya H (ed); Foundation TG (ed). Ankara University Press, Ankara (2000).

Conferences

  • Anstee QM; Concas D; Wu B; Potter P; Cox R; Kudo H; Levene A; Goldin RD; et alThursz MR; Thomas HC. A NOVEL MOUSE MODEL OF HEPATIC GLYCOGEN STORAGE DISEASE TYPE 3 IDENTIFIED USING A PHENOTYPE-DRIVEN ETHYL-NITROSOUREA (ENU) MUTAGENESIS SCREEN. 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), 2011. 54:S353-S353. ELSEVIER SCIENCE BV (1 Mar 2011). Author weblink.
  • Wadsworth CA; Dixon PH; Zabron AA; Wong JH; Chapman MH; McKay SC; Sharif AW; Spalding DR; et alPereira SP; Wasan HS; Thomas HC; Taylor-Robinson SD; Whittaker JC; Williamson C; Khan SA. GENETIC VARIATION IN BILIARY TRANSPORTERS AS A SUSCEPTIBILITY FACTOR FOR CHOLANGIOCARCINOMA. 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), 2011. 54:S109-S109. ELSEVIER SCIENCE BV (1 Mar 2011). Author weblink.
  • Wadsworth CA; Dixon PH; Zabron AA; Wong JH; Chapman MH; McKay SC; Spalding DR; Pereira SP; et alWasan HS; Thomas HC; Taylor-Robinson SD; Whittaker JC; Williamson C; Khan SA. COMMON GENETIC VARIATION IN NATURAL KILLER CELL RECEPTOR PROTEIN G2D DOES NOT MODIFY SUSCEPTIBILITY TO SPORADIC CHOLANGIOCARCINOMA. 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), 2011. 54:S108-S109. ELSEVIER SCIENCE BV (1 Mar 2011). Author weblink.
  • McPhail MJ; Leech R; Grover VP; Fitzpatrick J; Dhanjal NS; Saxby BK; Wesnes K; Thomas HC; et alWise RJ; Taylor-Robinson SD. FUNCTIONAL CORE MODULATION FOLLOWING TREATMENT OF MINIMAL HEPATIC ENCEPHALOPATHY WITH L-ORNITHINE L-ASPARTATE: A POTENTIAL NOVEL MECHANISM OF ACTION. 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), 2011. 54:S74-S75. ELSEVIER SCIENCE BV (1 Mar 2011). Author weblink.
  • Concas D; Wu B; Kudo H; Levene A; Thomas HC; Goldin RD; Thursz MR; Anstee QM. VANIN-1 ACTIVITY MODULATES THE STEATOSIS-STEATOHEPATITIS TRANSITION IN PROGRESSIVE NON-ALCOHOLIC STEATOHEPATITIS. 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), 2011. 54:S42-S43. ELSEVIER SCIENCE BV (1 Mar 2011). Author weblink.
  • Bridge SH; Sheridan DA; Felmlee D; Thomas H; Crossey M; Taylor-Robinson SD; Toms GL; Neely D; et alBassendine MF. APOLIPOPROTEIN E AND LOW-DENSITY, APOLIPOPROTEIN B ASSOCIATED LIPOVIRAL PARTICLES IN CHRONIC HEPATITIS C INFECTION: EVIDENCE FOR GENOTYPE-SPECIFIC MODULATION OF LIPID PATHWAYS. 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 4 Nov 2011 - 8 Nov 2011. 54:1316A-1316A. WILEY-BLACKWELL (1 Oct 2011). Author weblink.
  • Bridge SH; Sheridan DA; Felmlee D; Thomas H; Taylor-Robinson SD; Neely D; Toms GL; Bassendine MF. MEASUREMENT OF LOW-DENSITY APOLIPOPROTEIN B ASSOCIATED LIPOVIRAL PARTICLES IN HEPATITIS C VIRUS GENOTYPE 1 INFECTION IS MORE CLINICALLY RELEVANT THAN TOTAL VIRAL LOAD. 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 29 Oct 2010 - 2 Nov 2010. 52:435A-435A. WILEY-BLACKWELL (1 Oct 2010). Author weblink.
  • Wadsworth CA; Dixon PH; Zabron AA; Wong JH; Chapman MH; McKay SC; Spalding DR; Pereira SP; et alWasan HS; Thomas HC; Taylor-Robinson SD; Whittaker JC; Williamson C; Khan SA. GENETIC VARIATION IN NATURAL KILLER CELL RECEPTOR PROTEIN G2D DOES NOT MODIFY SUSCEPTIBILITY TO SPORADIC CHOLANGIOCARCINOMA. Annual Meeting on British-Society-of-Gasenterology, 14 Mar 2011 - 17 Mar 2011. 60. B M J PUBLISHING GROUP (1 Apr 2011). DOI.
  • Zabron AA; Horneffer-Van der Sluis VM; Geirula M; Wadsworth CA; Laird F; Thillainayagam AV; Vlavianos P; Westaby D; et alTaylor-Robinson SD; Edwards RJ; Khan SA. PROTEOMIC ANALYSIS OF BILE IN BENIGN AND MALIGNANT PANCREATOBILIARY DISEASE. Annual General Meeting of the British-Society-of-Gastroenterology, 22 Mar 2010 - 25 Mar 2010. 59:A82-A83. B M J PUBLISHING GROUP (1 Apr 2010). DOI.
  • Campbell L; Cook N; Roguin T; Marcinkowski H; Tooley V; Gellissen R; Brown A; Main J; et alThomas HC; Thursz MR. OPTIMISING TREATMENT OUTCOMES IN CHRONIC HEPATITIS C VIRUS INFECTION BY IMPROVING TREATMENT ADHERENCE RATES. Annual General Meeting of the British-Society-of-Gastroenterology, 22 Mar 2010 - 25 Mar 2010. 59:A78-A79. B M J PUBLISHING GROUP (1 Apr 2010). DOI.
  • Anstee QM; Possamai LA; Concas D; Wu B; Hassett C; Cox RD; Thomas HC; Thursz MR. NOVEL QUANTITATIVE TRAIT LOCUS FOR ACETAMINOPHEN-INDUCED HEPATOTOXICTY IDENTIFIED ON CHROMOSOME 18. 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 14 Apr 2010 - 18 Apr 2010. 52:S311-S311. ELSEVIER SCIENCE BV (1 Jan 2010). Author weblink.
  • Khan SA; Emadossadaty S; Taylor-Robinson SD; Elliott P; Thomas HC; Toledano MB. MISCLASSIFICATION OF HILAR (KLATSKIN) CHOLANGIOCARCINOMAS: AN INVESTIGATION OF CODING PRACTICE IN THE UK. 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 14 Apr 2010 - 18 Apr 2010. 52:S221-S221. ELSEVIER SCIENCE BV (1 Jan 2010). Author weblink.
  • Tooley V; Fitzpatrick JA; McPhail MJW; Campbell L; Cobbold JF; Thomas HC; Taylor-Robinson SD. CHEST CIRCUMFERENCE IS MORE IMPORTANT THAN BODY MASS INDEX IN DETERMINING AGREEMENT BETWEEN OPERATORS PERFORMING FIBROSCAN (R). 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 14 Apr 2010 - 18 Apr 2010. 52:S167-S167. ELSEVIER SCIENCE BV (1 Jan 2010). Author weblink.
  • McPhail M; Grover VP; Julie F; Saxby B; Thomas H; Taylor-Robinson SD. LONGITUDINAL ASSESSMENT OF BRAIN VOLUMES DURING TREATMENT OF CHRONIC HEPATIC ENCEPHALOPATHY WITH L-ORTHININE-L-ASPARTATE. 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 30 Oct 2009 - 3 Nov 2009. 50:434A-434A. JOHN WILEY & SONS INC (1 Oct 2009). Author weblink.
  • Adenugba A; Khan SA; Taylor-Robinson SD; Cox IJ; Toledano MB; Thillainayagam AV; Bansi DS; Gibson RW; et alThomas HC; Beck AC. POLYCHLORINATED BIPHENYLS IN BILE OF PATIENTS WITH BILIARY TRACT CANCER. 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 22 Apr 2009 - 26 Apr 2009. 50:S188-S188. ELSEVIER SCIENCE BV (1 Jan 2009). Author weblink.
  • Toledano MB; Mehtan A; Elliott P; Taylor-Robinson SD; Thomas HC; Khan SA. UPDATE OF INCIDENCE AND MORTALITY RATES AND REVIEW OF DIAGNOSTIC TRENDS FOR INTRAHEPATIC CHOLANGIOCARCINOMA AND SELECTED HEPATOBILIARY TUMOURS IN ENGLAND AND WALES. Annual Meeting of the British-Society-of-Gastroenterology, 23 Mar 2009 - 26 Mar 2009. 58:A67-A67. B M J PUBLISHING GROUP (1 Apr 2009). Author weblink.
  • Adenugba A; Khan SA; Taylor-Robinson SD; Cox I; Toledano MB; Thillainayagam AV; Bansi DS; Gibson RW; et alThomas HC; Beck AJ. POLYCHLORINATED BIPHENYLS IN BILE OF PATIENTS WITH BILIARY TRACT CANCER. Annual Meeting of the British-Society-of-Gastroenterology, 23 Mar 2009 - 26 Mar 2009. 58:A67-A67. B M J PUBLISHING GROUP (1 Apr 2009). Author weblink.
  • Knapp S; Hosie AM; Anstee QM; Thomos P; Mortensen M; Martinez A; Tymowska-Lalanne Z; McQuillin A; et alGurling HM; Morgan MY; Kuo Y-T; Herlihy A; Bell JD; Robinson I; Fisher E; Brown S; Stephens D; Smart TG; Thomas HC. IDENTIFICATION OF A MODEL OF ALCOHOL PREFERENCE AND ITS SIMILARITY TO HUMAN ALCOHOLISM. 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 31 Oct 2008 - 4 Nov 2008. 48:398A-399A. JOHN WILEY & SONS INC (1 Oct 2008). Author weblink.
  • Grover VP; Pavese N; Koh SB; Wylezinska M; McGuinness A; Saxby BK; Gerhard A; Forton DM; et alThomas HC; Brooks DJ; Taylor-Robinson SD. Evidence of neuroinflammation in patients with chronic hepatitis C: A cerebral positron emission tomography (PET) study. 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver. 48:S275-S275. (Feb 2008).
  • Cobbold JF; Patel N; Goldin RD; Crossey ME; Morin SH; Fitzpatrick JA; Arridge M; Cox IJ; et alThomas HC; Cosgrove DO; Thursz MR; Leen EL; Taylor-Robinson SD. Early haemodynamic responses to interferon therapy in patients with chronic liver disease using contrast-enhanced ultrasound: Regulation by hepatic stellate cells?. 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver. 48:S271-S271. (Feb 2008).
  • Cobbold JF; Chinthapalli S; Anstee Q; Goldin RD; Cox R; Thursz MR; Thomas HC; Taylor-Robinson SD; et alCox IJ. Dietary constituents in mice are reflected in the hepatic lipid profile as detected by carbon-13 magic angle spinning magnetic resonance spectroscopy. 58th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases. 46:764A-765A. (Oct 2007).
  • Kennedy P; Jeyalingam L; Lee H; Goldin R; Karayiannis P; Main J; Thursz MR; Brown A; et alSmith B; Thomas HC. Liver biopsy: Still essential in the management of chronic hepatitis B. 58th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2 Nov 2007 - 6 Nov 2007. 46:669A-669A. JOHN WILEY & SONS INC (1 Oct 2007). Author weblink.
  • Jammeh S; Thomas HC; Karayiannis P. Replicative competence of the T131I, K141E, and G145R surface variants of hepatitis B virus. 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases. 196:1010-1013. (1 Oct 2007).
  • Matthews HC; Absalom N; Goldsworthy M; Thomas HC; Goldin R; Thursz MR; Cox R. Buttermouse: The effect of high fat feeding on a new mouse model of insulin resistance and steatohepatitis. 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 11 Apr 2007 - 15 Apr 2007. 46:S276-S276. ELSEVIER SCIENCE BV (1 Jan 2007). Author weblink DOI.
  • Cobbold JF; Anstee QM; Goldin RD; Cox RD; Thursz MR; Thomas HC; Taylor-Robinson SD; Cox IJ. Can disease progression in non-alcoholic fatty liver disease be predicted by metabolic biomarkers of lipid accumulation and peroxidation?. 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 11 Apr 2007 - 15 Apr 2007. 46:S265-S265. ELSEVIER SCIENCE BV (1 Jan 2007). Author weblink DOI.
  • Anstee QM; Goldsworthy M; Goldin R; Thomas HC; Cox R; Thursz M. Microarray analysis demonstrates insulin resistance is central to NASH pathogenesis in the IGT/6 model and suggests a role for CEACAM-1 in disease pathogenesis. 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 11 Apr 2007 - 15 Apr 2007. 46:S261-S262. ELSEVIER SCIENCE BV (1 Jan 2007). Author weblink DOI.
  • Kallis YN; Scotton CJ; Goldin RD; Russo FP; Chambers RC; Thomas HC; Forbes SJ. PAR-1 knockout bone marrow stem cells can confer an anti-fibrotic phenotype to the injured liver. 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 11 Apr 2007 - 15 Apr 2007. 46:S129-S129. ELSEVIER SCIENCE BV (1 Jan 2007). Author weblink DOI.
  • Anstee QM; Goldsworthy M; Goldin R; Thomas HC; Cox RD; Thursz M. Microarray principal components analysis demonstrates expression of vanin-1 is a strong determinant of NASH pathogenesis in the IGT/6 model. 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 27 Oct 2006 - 31 Oct 2006. 44:243A-244A. JOHN WILEY & SONS INC (1 Oct 2006). Author weblink.
  • Hsieh F; Forton D; Thomas HC; Karayiannis R. Hepatitis C virus (HCV) internal ribosome entry site (IRES) variants from serum, liver and PBMCs and their translational efficiency in different cell lines. 12th International Symposium on Viral Hepatitis and Liver Disease, 1 Jul 2006 - 5 Jul 2006. 36:S116-S116. ELSEVIER SCIENCE BV (1 Jul 2006). Author weblink DOI.
  • Jammeh S; Thomas HC; Karayiannis P. Replication efficiency of hepatitis B virus infectious clones bearing core promoter, pre-core and surface gene mutations, in a common genetic background. 12th International Symposium on Viral Hepatitis and Liver Disease. 36:S52-S52. (Jul 2006).
  • Grover VP; Counsell SJ; Forton DM; Bradford EJ; Saxby BK; Thomas HC; Hajnal JV; Taylor-Robinson SD. Diffusion tensor and magnetisation transfer imaging of the brain at 3T in patients with cirrhosis and hepatic encephalopathy. 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 26 Apr 2006 - 30 Apr 2006. 44:S75-S76. ELSEVIER SCIENCE BV (1 Jan 2006). Author weblink DOI.
  • Forton DM; Allsop J; Thomas HC; Taylor-Robinson SD. Central nervous system involvement in hepatitis C virus infection: what to measure?. 12th International Symposium on Hepatic Encephalopathy and Nitrogen Metabolism. 284-290. (2006).
  • Thomas HC; Manns MP; Gish RG; Chang TT; Lai CL; Shouval D; Lok AS; Apelian D; et alFernandes L; Klesczewski K; Cross A; Wilber R. Decline in serum HBV DNA and alt normalization is associated with histologic response among nucleoside-naive patients in entecavir phase III trials. 40th Annual Meeting of the European-Association-for-the-Study-of-the-Liver. 42:192-193. (Apr 2005).
  • Amofah E; Russo FP; Bigger BW; Alison MR; Thomas HC; Forbes SJ. Gene delivery to the liver via the bone marrow. 40th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 13 Apr 2005 - 17 Apr 2005. 42:29-29. ELSEVIER SCIENCE BV (1 Apr 2005). Author weblink.
  • Waters J; Baltayiannis G; Forton DM; Tsianos E; Thomas HC; Karayiannis P. Internal ribosome entry site translational efficiencies of different members of the flaviviridae. 40th Annual Meeting of the European-Association-for-the-Study-of-the-Liver. 42:160-160. (Apr 2005).
  • Khan SA; Mandeville K; Toledano MB; Thomas HC; Taylor-Robinson SD. Update of mortality and incidence rates for intrahepatic cholangiocarcinoma and other hepatobiliary tumours in England and Wales. 40th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 13 Apr 2005 - 17 Apr 2005. 42:95-95. ELSEVIER SCIENCE BV (1 Apr 2005). Author weblink.
  • Azizah MTN; Durham A; Knapp S; Thomas HC; Thursz M; Frodsham AJ; Zhang L; Hill AV; et alGraves M. Functional variation in the IFNAR2 and IL10RB genes linked to persistent HBV infection. 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 29 Oct 2004 - 2 Nov 2004. 40:601A-601A. JOHN WILEY & SONS INC (1 Oct 2004). Author weblink.
  • Anstee QM; Wright M; Goldin R; Thomas HC; Thursz M. The factor V Leiden mutation accelerates disease progression in a mouse model of hepatic fibrosis induced by chronic carbon tetrachloride exposure. 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). 40:534A-535A. (Oct 2004).
  • Tillmann HL; Pradat P; Goldin R; Merle P; Thursz M; Langer J; Sauleda S; Saracco G; et alBadalamenti S; Alberti A; Braconier JH; Esteban JI; Hadziyannis S; Rizzetto M; Thomas HC; Manus MP; Trepo C. Anti-HBc positivity and gender are strongly related to HCC but are not related to treatment outcome. 39th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 14 Apr 2004 - 18 Apr 2004. 40:14-14. ELSEVIER SCIENCE BV (1 Apr 2004). Author weblink DOI.
  • Lim AKP; Patel N; Eckersley RJ; Bryant TH; Cosgrove DO; Thomas HC; Blomley MJ; Taylor-Robinson SD. Does microbubble ultrasound help with hepatocellular carcinoma screening in patients with HCV related liver disease?. Annual Meeting of the British-Society-of-Gastroenterology. 53:A79-A79. (Apr 2004).
  • Yee LJ; Knapp S; Burgner D; Hennig BJW; Frodsham AJ; Wright M; Thomas HC; Hill AVS; et alThursz MR. Inducible nitric oxide (NOS2A) haplotypes and the clinical outcomes of hepatitis C virus infection. 39th Annual Meeting of the European-Association-for-the-Study-of-the-Liver. 40:154-155. (Apr 2004).
  • Hellier S; Frodsham AJ; Hennig BJ; Knapp S; Wright M; Zhang L; Thomas HC; Thursz M; et alHill AVS. Association of genetic variants of the interferon alpha receptor-2 gene with outcome of treatment of persistant HCV infection. 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease. 38:457A-457A. (Oct 2003).
  • Wright M; Goldin RD; Hill AVS; Thomas HC; Thursz MR. Cholesteryl ester transfer protein (CETP)Ile405Val polymorphism affects the rate of fibrosis development in chronic hepatitis C virus infection. 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease. 38:334A-335A. (Oct 2003).
  • Wright M; Main J; Goldin RD; Thomas HC. Health benefits from anti viral therapy for mild chronic hepatitis C. A UK multi-centre randomised controlled trial. 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, 24 Oct 2003 - 28 Oct 2003. 38:318A-318A. W B SAUNDERS CO (1 Oct 2003). Author weblink.
  • Vig P; Thomas HC; Alison MR; Forbes SJ. The contribution of the bone marrow to liver regeneration depends upon the endogenous hepatocytes replication potential. 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, 24 Oct 2003 - 28 Oct 2003. 38:291A-291A. W B SAUNDERS CO (1 Oct 2003). Author weblink.
  • Forton DM; Karayiannis P; Mahmud N; Taylor-Robinson SD; Thomas HC. Identification of brain specific hepatitis C (HCV) variants and comparative analysis of translation efficiencies of internal ribosomal entry site (IRES) RNA sequences. Annual Meeting of the British-Association-for-the-Study-of-the-Liver. 52:U17-U18. (May 2003).
  • Khan SA; Cox IJ; Bansi D; Thillainayagam A; Thomas HC; Taylor-Robinson SD. Analysis of bile in patients with and without pancreaticobiliary malignancy by in vitro 31-phosphorus NMR spectroscopy. Annual meeting of the British-Society-of-Gastroenterology. 52:A92-A92. (Apr 2003).
  • Waters JA; Jones M; Jacobs M; Roberts P; Karayiannis P; Thomas HC; Foster GR. Effects of interferon on HCV and EMCV replication in the same cell line: Interferon inhibitory NS5A sequences do not inhibit the effects of IFN when expressed in the replicon. 38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver. 38:9-9. (Apr 2003).
  • Khan SA; Taylor-Robinson SD; Carmichael PL; Habib N; Lemoine N; Thomas HC. Novel p53 mutations but lack of a mutational fingerprint in human intrahepatic cholangiocarcinoma. Annual meeting of the British-Society-of-Gastroenterology, 23 Mar 2003 - 26 Mar 2003. 52:A32-A32. BRITISH MED JOURNAL PUBL GROUP (1 Apr 2003). Author weblink.
  • Hoare JM; Waddinton S; Thomas HC; Coutelle C; McGarvey M. Soluble complement receptor 1 (SCR1) prevents fatal toxicity following intra-portal administration of baculovirus vectors in mice. 38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver. 38:211-211. (Apr 2003).
  • Forton DM; Prince M; Allsop J; Patel N; Goldblatt J; Thomas HC; Bassendine M; Jones DEJ; et alTaylor-Robinson SD. Reduced pallidal magnetisation transfer ratios are associated with fatigue in pre-cirrhotic patients with primary biliary cirrhosis. 11th International Symposium on Hepatic Encephalopathy and Nitrogen Metabolism. 173-174. (2003).
  • Thomas HC; Thursz M; Frodsham A; Hill A. Host genetic factors influencing the outcome of HBV infection. Workshop on Therapies for Viral Hepatitis. 7:L89-L90. (Dec 2002).
  • Forton DM; Karayiannis P; Mahmud N; Taylor-Robinson S; Thomas HC. Identification of brain specific Hepatitis C (HCV) variants and comparative analysis of translation efficiencies of internal ribosomal entry site (IRES) RNA sequences. 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD), 1 Nov 2002 - 5 Nov 2002. 36:213A-213A. W B SAUNDERS CO (1 Oct 2002). Author weblink.
  • Karayiannis P; Foster G; Thomas HC. A new group of hepatitis inducing flaviviruses. 19th Annual General Meeting of the Association-of-Physicians-of-Great-Britain-and-Ireland, 11 Apr 1996 - 12 Apr 1996. 89:868-868. OXFORD UNIV PRESS UNITED KINGDOM (1 Nov 1996). Author weblink.
  • THOMAS HC; CARMAN WF. THE HOST IMMUNE-RESPONSE MAY BE RESPONSIBLE FOR SELECTION OF ENVELOPE AND PRECORE CORE VARIANTS OF HBV. INTERNATIONAL MEETING ON GENETIC HETEROGENEITY OF HEPATITIS VIRUSES : CLINICAL IMPLICATIONS. 13:S108-S113. (Apr 1991).
  • THOMAS HC. THE HEPATITIS-B VIRUS AND THE HOST RESPONSE. SYMP ON MANAGEMENT OF CHRONIC VIRAL HEPATITIS : FOCUS ON INTRON A ( INTERFERON ALFA 2B ), 8 Dec 1989 - 9 Dec 1989. 11:S83-S89. MUNKSGAARD INT PUBL LTD (1 Jan 1990). Author weblink DOI.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook